DS-8201, a blockbuster HER2-targeted ADC, is currently conducting a Phase II clinical trial of biliary tract cancer (BTC), which application is limited by the low HER2 amplification rate (5–20%) in BTC patients11. This evidence concerns the gene ERBB2 and biliary tract cancer.